NRG
MRVI icon

Nemes Rush Group’s Maravai LifeSciences MRVI Stock Holding History

Nemes Rush Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-207
Closed -$1.79K – 768
2024
Q3 		$1.79K Hold
207
– – ﹤0.01% 521
2024
Q2 		$1.48K Hold
207
– – ﹤0.01% 535
2024
Q1 		$1.79K Hold
207
– – ﹤0.01% 575
2023
Q4 		$1.36K Hold
207
– – ﹤0.01% 577
2023
Q3 		$2.07K Sell
207
-3,555
-94% -$39K ﹤0.01% 537
2023
Q2 		$46.8K Buy
+3,762
New +$50.8K 0.01% 272

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nemes Rush Group's MRVI Position: Q4 2024 in Review

Nemes Rush Group sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 207 shares — an estimated $1.79K sold.

Nemes Rush Group first reported a position in MRVI in Q2 2023 and held it in 6 quarters. The position peaked at $46.8K in Q2 2023. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Nemes Rush Group reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Nemes Rush Group sold 207 Maravai LifeSciences shares in Q4 2024, an estimated $1.79K.
  • Nemes Rush Group first reported a position in Maravai LifeSciences in Q2 2023 and held it in 6 quarters.
  • Nemes Rush Group's Maravai LifeSciences position peaked at $46.8K in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Nemes Rush Group's 13F filing for Q4 2024, filed 12 Feb 2025.